Aeluma (NASDAQ: ALMU) posts Q3 loss, tightens 2026 revenue guidance range
Rhea-AI Filing Summary
Aeluma, Inc. reported third quarter fiscal 2026 results showing modest revenue and ongoing investment-driven losses. Revenue for the three months ended March 31, 2026 was $1,222 thousand, while the company recorded a GAAP net loss of $1,800 thousand, or $(0.10) per basic and diluted share. For the nine-month period, revenue reached $3,879 thousand with a net loss of $5,146 thousand.
On a non-GAAP basis, which excludes items such as stock-based compensation and certain non-cash charges, Aeluma reported a third quarter net loss of $701 thousand and adjusted EBITDA of $(911) thousand. The company ended March 31, 2026 with $37,780 thousand in cash and cash equivalents, supporting its manufacturing and commercialization priorities.
Aeluma narrowed full fiscal 2026 revenue guidance to $4.2 million to $4.6 million, from a prior range of $4.0 million to $6.0 million, citing delays in contract execution related to government shutdowns and other factors. Management highlighted six new development engagements totaling $5 million and emphasized growing interest tied to AI data center and photonics demand.
Positive
- Strengthened balance sheet with higher cash: Cash and cash equivalents were $37,780 thousand as of March 31, 2026, supported by $23,385 thousand in net proceeds from a public offering plus additional warrant and option exercises, providing substantial liquidity for ongoing R&D and commercialization.
- Growing funded business activity: The company reported six new development engagements totaling $5 million in value and nine‑month revenue of $3,879 thousand versus $3,348 thousand in the prior‑year period, indicating an expanding base of commercial and development work.
Negative
- Narrowed and effectively lower revenue guidance: Full‑year fiscal 2026 revenue guidance was tightened to $4.2 million–$4.6 million from a prior range of $4.0 million–$6.0 million, reflecting delays in contract execution related to government shutdowns and other factors.
- Operating losses widen on higher spending: For the nine months ended March 31, 2026, Aeluma recorded a GAAP net loss of $5,146 thousand compared with $2,164 thousand in the prior‑year period, as total operating expenses more than doubled to $9,693 thousand.
Insights
Aeluma posts higher cash and growing backlog but tightens 2026 revenue outlook amid delays.
Aeluma generated Q3 fiscal 2026 revenue of $1,222 thousand with a GAAP net loss of $1,800 thousand, reflecting continued heavy spending on R&D and G&A. Non‑GAAP net loss improved to $701 thousand, and adjusted EBITDA was $(911) thousand.
For the nine months ended March 31, 2026, revenue reached $3,879 thousand while net loss widened to $5,146 thousand. Cash and cash equivalents increased sharply to $37,780 thousand, largely supported by a public offering that brought in $23,385 thousand net, plus warrant and option exercises.
The company narrowed full‑year fiscal 2026 revenue guidance to $4.2 million–$4.6 million, down from $4.0 million–$6.0 million, citing delays in contract start dates tied to government shutdowns and other factors. Management also highlighted six new development engagements totaling $5 million, which, together with strong cash, provide visibility into funded activity despite timing pressures.
8-K Event Classification
Key Figures
Key Terms
non-GAAP financial measures financial
Adjusted EBITDA financial
stock-based compensation financial
forward-looking statements regulatory
derivative liabilities financial
additional paid-in capital financial
Earnings Snapshot
Fiscal 2026 revenue guidance narrowed to $4.2 million–$4.6 million from a prior range of $4.0 million–$6.0 million.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 13, 2026, Aeluma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended March 31, 2026, which were disclosed in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 13, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information reported under this Item 2.02 of Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit
Number |
Exhibit | |
| 99.1 | Press Release of Aeluma, Inc. dated May 13, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AELUMA, INC. | ||
| Date: May 13, 2026 | By: | /s/ Jonathan Klamkin |
| Jonathan Klamkin | ||
| President, Chief Executive Officer, and Director | ||
2
Exhibit 99.1
Aeluma Announces Third Quarter Fiscal 2026 Financial Results
| ● | Recently Secured More Than $4 Million in Contracts for Quantum Dot Lasers and Materials |
| ● | Received NASA Award for Integrated Quantum Dot Lasers |
| ● | Announced Partnerships with Tower Semiconductor and Sumitomo Chemical Advanced Technologies for Wafer Production and Fabrication |
| ● | Appointed Vice President of Materials Operations and Vice President of Strategic Partnerships and Ecosystem |
| ● | Cash and Cash Equivalents as of March 31, 2026 of $37.8 Million |
GOLETA, CA – May 13, 2026 – Aeluma, Inc. (NASDAQ: ALMU) (“Aeluma” or the “Company”), a transformative semiconductor company specializing in high-performance and scalable technologies, today reported financial results for its third quarter of fiscal 2026 ended March 31, 2026.
Management Commentary
“This quarter reinforced Aeluma’s strategy as we have experienced a major uptick in commercial interest,” said Jonathan Klamkin, Ph.D., Founder and CEO of Aeluma. “The massive AI data center buildout is outpacing the scale of the photonics supply chain. Customers are considering our technology to address near-term supply gaps, and for long-term growth opportunities.”
“The industry is experiencing constraints around indium phosphide technology that we highlighted years ago—and that dynamic is creating both urgency and opportunity for Aeluma,” Dr. Klamkin continued. “These market forces validate the core thesis behind our platform and underscore the relevance of the solutions we’ve been developing.”
“We have made considerable progress in our commercialization path with important manufacturing partnerships to enable scaling, senior hires to support operations and strategy, and additional non-dilutive capital. With six new development engagements totaling $5 million in value, we have already met our objective of onboarding three to seven new contracts for fiscal 2026.”
“Our recent participation at the Optical Fiber Communication (OFC) Conference reinforced that the industry is looking beyond short-term fixes and toward platforms that can enable long-term growth. That shift in perspective plays directly to Aeluma’s strengths. Beyond AI infrastructure, we continue to advance opportunities across mobile, defense, and quantum. Engagements are becoming more targeted and more closely aligned with commercialization paths,” concluded Dr. Klamkin.
Recent Company Highlights
| ● | Growing Market Traction and Visibility: Increased engagement with customers, partners, and government agencies across AI datacom, mobile, defense, and quantum. Highly successful participation at OFC in Los Angeles, California, AngelTech Innovate Summit in Brussels, Belgium, and SPIE Defense + Security Conference in National Harbor, Maryland. |
| ● | Leadership and Team Expansion: Added experienced leadership and technical talent, including Christiane Poblenz, Ph.D., as Vice President of Materials Operations in March, Willy Rachmady, Ph.D., as Vice President of Strategic Partnerships and Ecosystem in April, as well as other key hires in operations and engineering. |
| ● | Expanded Engagements with Manufacturing Partners: Strengthened relationships with manufacturing partners to accelerate transition to production, including announced partnerships with Tower Semiconductor and Sumitomo Chemical Advanced Technology. |
| ● | Continued R&D Contracts Progress: Achieved fiscal 2026 goal of three to seven new contracts with six contracts to date totaling $5 million in value. Recent contracts include more than $4 million from U.S. government agencies to accelerate scaling Aeluma’s semiconductor heterogeneous integration platform for laser, high-speed datacom, and quantum applications. Also, received NASA funding to accelerate commercialization of integrated quantum dot lasers for silicon photonics. |
| ● | Expanded Intellectual Property Portfolio: Continued to advance portfolio with two provisional applications, nine nonprovisional applications and continuations, and seven patents issued. The total number of issued and pending patents is 36. |
Fiscal Q3 2026 Financial Results
| ● | Revenue was $1.2 million compared to $1.3 million in the third quarter of 2025, and $1.3 million in the second quarter of 2026. Revenue in the quarter was primarily from R&D contracts. |
| ● | GAAP net loss was $1.8 million, or $0.10 per basic and diluted share, compared to a net gain of $1.5 million, or $0.12 per basic share and $0.11 per diluted share, for the same period last year and net loss of $1.9 million, or ($0.11) per basic and diluted share, in the prior quarter. The year-over-year change in net income was primarily due to a one-time $2.3 million gain in the fair value of derivative liabilities recorded in the third quarter of fiscal 2025. |
| ● | Adjusted EBITDA loss was $911 thousand, compared to a gain of $109 thousand in the same period last year, and in line with the prior quarter. Adjusted EBITDA loss increased year over year primarily due to higher salaries, stock-based compensation and employee benefits for new key positions to support business expansion and scaling operations. |
| ● | Cash and cash equivalents totaled $37.8 million at March 31, 2026, compared to $38.6 million at December 31, 2025. |
Fiscal Year 2026 Guidance and Strategic Priorities
For the full fiscal year of 2026, Aeluma narrowed its previous revenue guidance to $4.2 million to $4.6 million from the previous range of $4.0 million to $6.0 million. Delays in execution of contracts, due to government shutdowns and other factors, led to postponement of initial start-of-work for several projects. The Company has made considerable progress on its strategic priorities for 2026, which emphasize manufacturing and commercialization moving forward:
| ● | New Contract Wins: Achieved 2026 goal of three to seven new contracts with six contracts to date totaling $5 million in value, which provide non-dilutive funding for R&D and the growth of partnership opportunities. |
2
| ● | Team Expansion: Attracted top talent for key roles including Senior Vice President of Business Development and Product, Vice President of Operations, Vice President of Strategic Partnerships and Ecosystem, and others, to support growth of our business development and go-to-market team, technical leadership and staff, and operations team. |
| ● | Enhanced Manufacturing Readiness: Increased outsourced wafer manufacturing productivity and advanced supply chain partnerships including recently announced relationships with Tower Semiconductor and Sumitomo Chemical Advanced Technology. |
| ● | Go-to-Market Traction: Product roadmap being driven by continued progress in target commercial markets across mobile and consumer electronics, photonics for AI infrastructure, and defense and aerospace. |
Conference Call and Webcast
Aeluma will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on May 13, 2026, to discuss the Company’s financial results and business outlook. Interested participants may access the conference the call by dialing (877) 317-6789 (domestic) or (412) 317-6789 (international) and referencing “Aeluma.” A live webcast of the call will be available on the “Investors” section of Aeluma’s website and can also be accessed by clicking here. A replay of the conference call will be available on Aeluma’s website shortly after the call concludes.
Note about Non-GAAP Financial Measures
This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Aeluma believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations. Aeluma believes that these non-GAAP financial measures provide additional insight into Aeluma’s ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Aeluma’s results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation and amortization.
This press release includes non-GAAP financial measures, including:
| ● | Non-GAAP net income (loss), which is defined as GAAP net income (loss) plus stock-based compensation expenses, amortization of discount on convertible notes, and changes in fair value of derivative liabilities; and |
| ● | Adjusted EBITDA, defined as non-GAAP net income (loss) plus depreciation and amortization expenses, less interest income. |
A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.
3
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
About Aeluma, Inc.
Aeluma (NASDAQ: ALMU) is a transformative semiconductor company specializing in high-performance photonic and electronic technologies that scale. The company’s proprietary platform combines compound semiconductors with scalable manufacturing used for mass market microelectronics to enable volume production and large-scale integration. Applications for Aeluma’s technology include mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum. Headquartered in Goleta, California, Aeluma operates state-of-the-art R&D and manufacturing capabilities for semiconductor wafer production, quick-turn chip fabrication, rapid prototyping, test and validation. Aeluma also partners with production-scale fabrication foundries, packaging, and integration companies. For more information, visit www.aeluma.com.
Company:
Aeluma, Inc.
(805) 351-2707
info@aeluma.com
Investor Contact:
Financial Profiles, Inc.
Alex Villalta
(310) 622-8227
ir@aeluma.com
4
Aeluma, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| ($ in thousands) | March 31, (unaudited) | June 30, 2025 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 37,780 | $ | 3,628 | ||||
| Certificate of deposit | - | 12,112 | ||||||
| Accounts receivable | 1,062 | 962 | ||||||
| Prepaids and other current assets | 1,332 | 633 | ||||||
| Total current assets | 40,174 | 17,335 | ||||||
| Property and equipment: | ||||||||
| Equipment | 2,131 | 1,692 | ||||||
| Leasehold improvements | 547 | 547 | ||||||
| Accumulated depreciation | (1,344 | ) | (1,021 | ) | ||||
| Property and equipment, net | 1,334 | 1,218 | ||||||
| Right of use asset - operating | 987 | 836 | ||||||
| Other assets | 22 | 17 | ||||||
| Total assets | $ | 42,517 | $ | 19,406 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 973 | $ | 361 | ||||
| Accrued expenses and other current liabilities | 370 | 206 | ||||||
| Lease liability - operating, current portion | 196 | 138 | ||||||
| Total current liabilities | 1,539 | 705 | ||||||
| Lease liability - operating, long-term portion | 893 | 803 | ||||||
| Total liabilities | 2,432 | 1,508 | ||||||
| Commitments and contingencies | - | - | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | - | - | ||||||
| Common stock | 2 | 2 | ||||||
| Additional paid-in capital | 61,875 | 34,542 | ||||||
| Accumulated deficit | (21,792 | ) | (16,646 | ) | ||||
| Total stockholders’ equity | 40,085 | 17,898 | ||||||
| Total liabilities and stockholders’ equity | $ | 42,517 | $ | 19,406 | ||||
5
Aeluma, Inc. and Subsidiary
Condensed Consolidated Statements of Operations (unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| ($ in thousands, except per share data) | March 31, 2026 | December 31, 2025 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||||
| Revenue | $ | 1,222 | $ | 1,272 | $ | 1,255 | $ | 3,879 | $ | 3,348 | ||||||||||
| Operating expenses: | ||||||||||||||||||||
| Cost of revenue | 836 | 919 | 311 | 2,456 | 1,105 | |||||||||||||||
| Research and development | 882 | 906 | 471 | 2,394 | 1,130 | |||||||||||||||
| General and administrative | 1,629 | 1,528 | 1,305 | 4,843 | 2,287 | |||||||||||||||
| Total operating expenses | 3,347 | 3,353 | 2,087 | 9,693 | 4,522 | |||||||||||||||
| Loss from operations | (2,125 | ) | (2,081 | ) | (832 | ) | (5,814 | ) | (1,174 | ) | ||||||||||
| Other income (expense): | ||||||||||||||||||||
| Interest income | 325 | 228 | 3 | 668 | 3 | |||||||||||||||
| Amortization of discount on convertible notes | - | - | (287 | ) | - | (715 | ) | |||||||||||||
| Changes in fair value of derivative liabilities | - | - | 2,577 | - | (278 | ) | ||||||||||||||
| Total other income (expense), net | 325 | 228 | 2,293 | 668 | (990 | ) | ||||||||||||||
| Income (loss) before income tax expense | (1,800 | ) | (1,853 | ) | 1,461 | (5,146 | ) | (2,164 | ) | |||||||||||
| Income tax expense | - | - | - | - | - | |||||||||||||||
| Net income (loss) | $ | (1,800 | ) | $ | (1,853 | ) | $ | 1,461 | $ | (5,146 | ) | $ | (2,164 | ) | ||||||
| Net income (loss) per share: | ||||||||||||||||||||
| Basic | $ | (0.10 | ) | $ | (0.11 | ) | $ | 0.12 | $ | (0.30 | ) | $ | (0.18 | ) | ||||||
| Diluted | $ | (0.10 | ) | $ | (0.11 | ) | $ | 0.11 | $ | (0.30 | ) | $ | (0.18 | ) | ||||||
| Weighted average common shares outstanding: | ||||||||||||||||||||
| Basic | 18,061,402 | 17,875,930 | 12,472,061 | 17,354,370 | 12,286,284 | |||||||||||||||
| Diluted | 18,061,402 | 17,875,930 | 13,206,919 | 17,354,370 | 12,286,284 | |||||||||||||||
| Book value per share | $ | 2.22 | $ | 2.28 | $ | 1.44 | $ | 2.22 | $ | 1.44 | ||||||||||
6
Aeluma, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows (unaudited)
| Nine Months Ended March 31, | ||||||||
| ($ in thousands) | 2026 | 2025 | ||||||
| Operating activities: | ||||||||
| Net loss | $ | (5,146 | ) | $ | (2,164 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Amortization of deferred compensation | - | 17 | ||||||
| Stock-based compensation expense | 3,211 | 1,149 | ||||||
| Depreciation and amortization expense | 325 | 307 | ||||||
| Amortization of discount on convertible notes | - | 715 | ||||||
| Changes in fair value of derivative liabilities | - | 278 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (100 | ) | (1,083 | ) | ||||
| Prepaids and other current assets | (699 | ) | (192 | ) | ||||
| Other assets | (7 | ) | - | |||||
| Accounts payable | 612 | (144 | ) | |||||
| Accrued expenses and other current liabilities | 161 | 34 | ||||||
| Net cash used in operating activities | (1,643 | ) | (1,083 | ) | ||||
| Investing activities: | ||||||||
| Purchase of equipment | (439 | ) | (85 | ) | ||||
| Net cash used in investing activities | (439 | ) | (85 | ) | ||||
| Financing activities: | ||||||||
| Proceeds from stock option exercise | 103 | 10 | ||||||
| Proceeds from stock warrant exercise | 690 | - | ||||||
| Proceeds from convertible notes issuance | - | 3,145 | ||||||
| Proceeds from public offering, net of offering costs | 23,385 | 12,587 | ||||||
| Payment for taxes related to net share settlement of restricted stock units | (56 | ) | - | |||||
| Net cash provided by financing activities | 24,122 | 15,742 | ||||||
| Net change in cash and cash equivalents, and certificate of deposit | 22,040 | 14,574 | ||||||
| Cash and cash equivalents, and certificate of deposit, beginning of period | 15,740 | 1,291 | ||||||
| Cash and cash equivalents, and certificate of deposit, end of period | $ | 37,780 | $ | 15,865 | ||||
| Supplemental non-cash disclosures: | ||||||||
| Right of use asset - operating obtained in exchange for lease liability - operating | $ | 274 | $ | - | ||||
| Conversion of convertible notes to stockholders’ equity | $ | - | $ | 1,667 | ||||
| Conversion of derivative liabilities to stockholders’ equity | $ | - | $ | 2,471 | ||||
7
Aeluma, Inc. and Subsidiary
Reconciliation of GAAP and Non-GAAP Financial Measures (unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||||||
| ($ in thousands, except per share data) | March 31, 2026 | December 31, 2025 | March 31, 2025 | March 31, 2026 | March 31, 2025 | |||||||||||||||
| GAAP net income (loss) | $ | (1,800 | ) | $ | (1,853 | ) | $ | 1,461 | $ | (5,146 | ) | $ | (2,164 | ) | ||||||
| Non-GAAP adjustments: | ||||||||||||||||||||
| Stock-based compensation | 1,099 | 1,056 | 833 | 3,211 | 1,149 | |||||||||||||||
| Consulting and advisory | - | - | 3 | - | 17 | |||||||||||||||
| Amortization of discount on convertible notes | - | - | 287 | - | 715 | |||||||||||||||
| Changes in fair value of derivative liabilities | - | - | (2,577 | ) | - | 278 | ||||||||||||||
| Total adjustments to GAAP net loss | 1,099 | 1,056 | (1,454 | ) | 3,211 | 2,159 | ||||||||||||||
| Non-GAAP net income (loss) | $ | (701 | ) | $ | (797 | ) | $ | 7 | $ | (1,935 | ) | $ | (5 | ) | ||||||
| Depreciation & amortization | 115 | 108 | 105 | 325 | 307 | |||||||||||||||
| Interest income | (325 | ) | (228 | ) | (3 | ) | (668 | ) | (3 | ) | ||||||||||
| Adjusted EBITDA | $ | (911 | ) | $ | (917 | ) | $ | 109 | $ | (2,278 | ) | $ | 299 | |||||||
| GAAP net income (loss) per share – basic | $ | (0.10 | ) | $ | (0.11 | ) | $ | 0.12 | $ | (0.30 | ) | $ | (0.18 | ) | ||||||
| Non-GAAP adjustments | 0.06 | 0.07 | (0.12 | ) | 0.19 | 0.18 | ||||||||||||||
| Non-GAAP net loss per share – basic | $ | (0.04 | ) | $ | (0.04 | ) | $ | - | $ | (0.11 | ) | $ | - | |||||||
| GAAP net income (loss) per share – diluted | $ | (0.10 | ) | $ | (0.11 | ) | $ | 0.11 | $ | (0.30 | ) | $ | (0.18 | ) | ||||||
| Non-GAAP adjustments | 0.06 | 0.07 | (0.11 | ) | 0.19 | 0.18 | ||||||||||||||
| Non-GAAP net loss per share – diluted | $ | (0.04 | ) | $ | (0.04 | ) | $ | - | $ | (0.11 | ) | $ | - | |||||||
8